United States, Boston\China, Shanghai-Recently, Anji Pharmaceuticals, a biopharmaceutical company invested and incubated by the VivaBioInnovator, announced that the world's first mechanism of functional constipation treatment drug pradigastat (ANJ908) Phase II clinical proof of concept research has been initiated simultaneously in the United States and China. Despite the challenge of the global epidemic, the study is still progressing smoothly, and many subjects have completed medication.
is a first-in-class inhibitor of diacylglycerol acyltransferase 1 (DGAT1), which has demonstrated excellent safety and unique mechanism of action in multiple clinical studies. Compared with existing drugs, ANJ908 is expected to greatly increase the treatment response rate, and become the best therapy for constipation-related indications.Anji Pharmaceutical has the global development and commercialization rights of ANJ908 in constipation-related indications, as well as a global patent for treating constipation-related indications with DGAT1 as the target.
About Anji PharmaceuticalAnji Pharma is a clinical-stage biotech company with operations in the U.S., Beijing, and Shanghai. Our deep science expertise and our innate problem-solving enable Anji to bring medicines to patients around the world – quickly and safely.
